Author: admin

Beta Thalassemia Market Size and Share 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight

“Beta Thalassemia Market”
Beta Thalassemia companies working in the market are Novartis, Merck, Bristol Myers Squibb, Celgene, Chiesi Farmaceutici S.p.A, Bluebird Bio, Agios Pharmaceuticals, Imara Inc., CRISPR Therapeutics, Vertex Pharmaceuticals, Vifor Pharma, Ionis Pharmaceuticals, Forma Therapeutics, DisperSol Technologies, EdiGene, SILENCE Therapeutics, and others.

(Albany, USA) DelveInsight’s “Beta Thalassemia Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Beta Thalassemia, historical and forecasted epidemiology as well as the Beta Thalassemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Beta Thalassemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Beta Thalassemia market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Beta Thalassemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Beta Thalassemia market.

 

Request for a Free Sample Report @ Beta Thalassemia Market Forecast

 

Some facts of the Beta Thalassemia Market Report are:

  • According to DelveInsight, Beta Thalassemia market size is expected to grow at a decent CAGR by 2034.
  • Leading Beta Thalassemia companies working in the market are Novartis, Merck, Bristol Myers Squibb, Celgene, Chiesi Farmaceutici S.p.A, Bluebird Bio, Agios Pharmaceuticals, Imara Inc., CRISPR Therapeutics, Vertex Pharmaceuticals, Vifor Pharma, Ionis Pharmaceuticals, Forma Therapeutics, DisperSol Technologies, EdiGene, SILENCE Therapeutics, and others.
  • Key Beta Thalassemia Therapies expected to launch in the market are ET-01, CTX001 – a Phase II/III Cell replacement therapy, Mitapivat – a Phase III Pyruvate Kinase stimulant, Zynteglo- Phase III Gene therapy, IMR-687 (Imara Inc.), Sapablursen (Ionis Pharmaceuticals), ACE-536, DST-0509 (DisperSol Technology), SLN 124 (Silence Therapeutics), and many more.
  • In May 2025, Celgene announced a Phase 2a Study to Evaluate the Safety and Pharmacokinetics of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
  • In May 2025, Celgene announced results of a Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
  • In April 2025, Vertex Pharmaceuticals announced results of a Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease
  • In March 2025, Kanglin Biotechnology (Hangzhou) Co., Ltd announced results of a Phase I/II Clinical Study Evaluating the Safety and Efficacy of KL003 Cell Injection in Transfusion-dependent Β-thalassemia
  • In January 2025, Agios Pharmaceuticals (AGIO) announced that the FDA has accepted its supplemental new drug application (sNDA) to expand the label of Pyrukynd, its sole marketed drug, to include the treatment of thalassemia.
  • In January 2025, YolTech Therapeutics is preparing to launch a clinical trial for YOLT-204, its in vivo gene-editing therapy designed to treat transfusion-dependent beta-thalassemia (TDT). TDT is a genetic blood disorder caused by mutations in the beta-globin gene, leading to reduced or absent hemoglobin production. Patients with this condition require regular blood transfusions to manage anemia and prevent future complications.
  • In 2023, the Beta-thalassemia market size in the US was around USD 358 million, with expectations of significant growth by 2034, driven by a substantial Compound Annual Growth Rate (CAGR) during the study period (2020–2034).
  • The Beta-thalassemia market size in EU4 and the UK was around USD 356 million and is anticipated to grow during the forecast period.
  • Among European countries, Italy had the largest Beta-thalassemia market size, reaching approximately USD 241 million in 2023.

 

Beta Thalassemia Overview

Beta thalassemia is an inherited blood disorder characterized by reduced production of hemoglobin, the protein in red blood cells that carries oxygen. This condition arises due to mutations in the HBB gene, affecting the synthesis of beta-globin chains, a component of hemoglobin. Individuals with beta thalassemia may experience anemia, fatigue, pale skin, and jaundice due to insufficient healthy red blood cells. The severity varies, classified into thalassemia major, intermedia, or minor, based on the number of affected genes and symptoms. Treatment includes blood transfusions, iron chelation therapy to manage iron overload from transfusions, and occasionally, bone marrow transplants. Patients often require lifelong medical care, emphasizing the importance of genetic counseling and early detection through prenatal testing for at-risk families.

 

Learn more about Beta Thalassemia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Beta Thalassemia Treatment Market

 

Beta Thalassemia Market

The Beta Thalassemia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Beta Thalassemia market trends by analyzing the impact of current Beta Thalassemia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Beta Thalassemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Beta Thalassemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Beta Thalassemia market in 7MM is expected to witness a major change in the study period 2020-2034.

 

Beta Thalassemia Epidemiology

The Beta Thalassemia epidemiology section provides insights into the historical and current Beta Thalassemia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Beta Thalassemia market report also provides the diagnosed patient pool, trends, and assumptions.

 

Explore more about Beta Thalassemia Epidemiology @ Beta Thalassemia Patient Population

 

Beta Thalassemia Drugs Uptake

This section focuses on the uptake rate of the potential Beta Thalassemia drugs recently launched in the Beta Thalassemia market or expected to be launched in 2020-2034. The analysis covers the Beta Thalassemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Beta Thalassemia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Beta Thalassemia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Beta Thalassemia Pipeline Development Activities

The Beta Thalassemia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Beta Thalassemia key players involved in developing targeted therapeutics.

 

Request for a sample report to understand more about the Beta Thalassemia pipeline development activities @ Beta Thalassemia Medication and Companies

 

Beta Thalassemia Therapeutics Assessment

Major key companies are working proactively in the Beta Thalassemia Therapeutics market to develop novel therapies which will drive the Beta Thalassemia treatment markets in the upcoming years are Novartis, Merck, Bristol Myers Squibb, Celgene, Chiesi Farmaceutici S.p.A, Bluebird Bio, Agios Pharmaceuticals, Imara Inc., CRISPR Therapeutics, Vertex Pharmaceuticals, Vifor Pharma, Ionis Pharmaceuticals, Forma Therapeutics, DisperSol Technologies, EdiGene, SILENCE Therapeutics, and others.

 

Learn more about the emerging Beta Thalassemia therapies & key companies @ Beta Thalassemia Clinical Trials and FDA Approvals

 

Beta Thalassemia Report Key Insights

1. Beta Thalassemia Patient Population

2. Beta Thalassemia Market Size and Trends

3. Key Cross Competition in the Beta Thalassemia Market

4. Beta Thalassemia Market Dynamics (Key Drivers and Barriers)

5. Beta Thalassemia Market Opportunities

6. Beta Thalassemia Therapeutic Approaches

7. Beta Thalassemia Pipeline Analysis

8. Beta Thalassemia Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Beta Thalassemia Market

 

Table of Contents

 

1. Key Insights

2. Executive Summary

3. Beta Thalassemia Competitive Intelligence Analysis

4. Beta Thalassemia Market Overview at a Glance

5. Beta Thalassemia Disease Background and Overview

6. Beta Thalassemia Patient Journey

7. Beta Thalassemia Epidemiology and Patient Population

8. Beta Thalassemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Beta Thalassemia Unmet Needs

10. Key Endpoints of Beta Thalassemia Treatment

11. Beta Thalassemia Marketed Products

12. Beta Thalassemia Emerging Therapies

13. Beta Thalassemia Seven Major Market Analysis

14. Attribute Analysis

15. Beta Thalassemia Market Outlook (7 major markets)

16. Beta Thalassemia Access and Reimbursement Overview

17. KOL Views on the Beta Thalassemia Market

18. Beta Thalassemia Market Drivers

19. Beta Thalassemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Beta Thalassemia Market Size and Share 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight

Dravet Syndrome Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

“Dravet Syndrome Treatment Market”
Dravet Syndrome Companies are Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Inc, Zogenix International Ltd, Inc., Jazz Pharmaceuticals, Ovid Therapeutics Inc., Longboard Pharmaceuticals, and others

(Albany, USA) DelveInsight’s “Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Dravet Syndrome market report provides current treatment practices, emerging drugs, the Dravet Syndrome market share of individual therapies, and current and forecasted Dravet Syndrome market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Dravet Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

To Know in detail about the Dravet Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dravet Syndrome Market Forecast

 

Some of the key facts of the Dravet Syndrome Market Report:

  • The Dravet Syndrome market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In January 2025, Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on restoring protein expression through RNA-based medicine, has reached an agreement with global regulatory agencies on the design of its Phase 3 EMPEROR study. This trial aims to evaluate zorevunersen as a potential first disease-modifying treatment for Dravet syndrome.
  • In January 2025, The FDA awarded rare pediatric disease designation to relutrigine, a therapy developed by Praxis Precision Medicines for Dravet syndrome. This treatment is designed to help reduce seizures in children with epileptic disorders such as Dravet syndrome.
  • In December 2024, Stoke Therapeutics, Inc. announced that the FDA has granted Breakthrough Therapy Designation to zorevunersen for treating Dravet syndrome in patients with a confirmed SCN1A gene mutation that is not linked to gain-of-function.
  • In February 2024, The FDA has approved Encoded Therapeutics’ investigational new drug (IND) application for ETX101, allowing the company to initiate clinical trials for this gene therapy candidate aimed at treating Sodium channel protein type 1 subunit alpha (SCN1A)+ Dravet syndrome. Additionally, Australia’s TGA has granted approval under its Clinical Trial Approval (CTA) scheme for the trial to begin. ETX101 is an AAV9-mediated gene regulation therapy designed to enhance SCN1A gene expression in GABAergic inhibitory interneurons, targeting the root cause of Dravet syndrome. Encoded plans to launch a two-part Phase I/II clinical trial called ENDEAVOR in the US for patients aged six months to under three years in the first half of this year.
  • A new US epidemiological study, according to the Dravet Syndrome Foundation (2022), found that the prevalence of Dravet Syndrome, which affects 1:15,700 infants and 80% of whom had a SCN1A mutation, is twice as high as previously thought
  • The predicted total number of diagnosed cases of Dravet Syndrome in France in 2022 was 1,050, and by 2032, that number is expected to rise
  • It is projected that there will be approximately 1,000 treated instances of Dravet syndrome in the UK in 2022, and that number will rise by 2032
  • As to the company’s declaration, FINTEPLA’s net product sales amounted to around $75 million. In a similar vein, EPIDIOLEX’s net product sales in 2021 totaled $463.6 million.
  • A number of the newly developed Dravet syndrome treatments are in the late stages of clinical testing. These include lorcaserin and TAK-935 (soticlestat), both of which have demonstrated great promise in trials
  • Key Dravet Syndrome Companies: Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Inc, Zogenix International Ltd, Inc., Jazz Pharmaceuticals, Ovid Therapeutics Inc., Longboard Pharmaceuticals, and others
  • Key Dravet Syndrome Therapies: TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ganaxolone, EPX-100 (Clemizole HCl), STK-001, ZX008 (Fenfluramine Hydrochloride), GWP42003-P, Soticlestat, LP352, and others
  • The Dravet Syndrome epidemiology based on gender analyzed that more men than women have Dravet Syndrome
  • The Dravet Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dravet Syndrome pipeline products will significantly revolutionize the Dravet Syndrome market dynamics.

 

Dravet Syndrome Overview

Dravet Syndrome is a rare and severe form of epilepsy that typically begins in infancy. Dravet Syndrome symptoms often appear in the first year of life, commonly triggered by fever or illness. Dravet Syndrome seizures are prolonged, difficult to control, and may evolve into multiple types including myoclonic, focal, and generalized tonic-clonic seizures. Dravet Syndrome is most frequently caused by mutations in the SCN1A gene, leading to dysfunctional sodium channels in the brain. Dravet Syndrome diagnosis involves genetic testing and clinical evaluation based on seizure history and development.

Dravet Syndrome significantly impacts cognitive, behavioral, and motor development. Dravet Syndrome treatment includes antiepileptic medications like stiripentol, cannabidiol (CBD), and fenfluramine, often in combination for better seizure control. Dravet Syndrome management also involves seizure first-aid awareness, avoiding known triggers, and personalized care plans. Dravet Syndrome research is ongoing, exploring gene therapy and precision medicine as potential future treatments.

Dravet Syndrome prognosis varies, but early intervention and comprehensive care can improve quality of life. Dravet Syndrome support from healthcare professionals, caregivers, and advocacy groups is essential for long-term care. Dravet Syndrome awareness is crucial for early diagnosis, improved outcomes, and enhanced support for affected families worldwide.

 

Get a Free sample for the Dravet Syndrome Market Report: Dravet Syndrome Treatment Market

 

Dravet Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Dravet Syndrome Epidemiology Segmentation:

The Dravet Syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Dravet Syndrome
  • Prevalent Cases of Dravet Syndrome by severity
  • Gender-specific Prevalence of Dravet Syndrome
  • Diagnosed Cases of Episodic and Chronic Dravet Syndrome

 

Download the report to understand which factors are driving Dravet Syndrome epidemiology trends @ Dravet Syndrome Epidemiology Forecast

 

Dravet Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dravet Syndrome market or expected to get launched during the study period. The analysis covers Dravet Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dravet Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Dravet Syndrome Therapies and Key Companies

  • TAK-935 (soticlestat): Takeda
  • BELVIQ (lorcaserin): Eisai
  • STK-001: Stoke Therapeurtics
  • EPX-100: EpyGenix Therapeutics
  • ganaxolone: Marinus Pharmaceuticals
  • EPX-100 (Clemizole HCl): Epygenix
  • STK-001: Stoke Therapeutics, Inc
  • ZX008 (Fenfluramine Hydrochloride): Zogenix International Ltd, Inc.
  • Soticlestat: Takeda
  • GWP42003-P: Jazz Pharmaceuticals
  • Soticlestat: Ovid Therapeutics Inc.
  • LP352: Longboard Pharmaceuticals

 

Discover more about therapies set to grab major Dravet Syndrome market share @ Dravet Syndrome Treatment Market

 

Dravet Syndrome Market Strengths

  • The researchers are undergoing advancement in already approved drugs by providing an alternative means of delivering the drug.
  • A broader awareness among health care providers and the public for better treatments helps to improve care and outcomes.
  • Development of long-acting injectable Antipsychotics.

 

Dravet Syndrome Market Opportunities

  • Demands of advanced therapeutics and presence of significant number of pipeline drugs.
  • There is growing evidence that patients with a dual diagnosis does not respond well to conventional psychiatric treatment, creating demand for a new approach from a different perspective.
  • Because of the increase in the side effects and less efficacious drug, the demand for specific therapy also increases.

 

Scope of the Dravet Syndrome Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Dravet Syndrome Therapies: TAK-935 (soticlestat), BELVIQ (lorcaserin), STK-001, ganaxolone, EPX-100 (Clemizole HCl), STK-001, ZX008 (Fenfluramine Hydrochloride), GWP42003-P, Soticlestat, LP352, and others
  • Dravet Syndrome Therapeutic Assessment: Dravet Syndrome current marketed and Dravet Syndrome emerging therapies
  • Dravet Syndrome Market Dynamics: Dravet Syndrome market drivers and Dravet Syndrome market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Dravet Syndrome Unmet Needs, KOL’s views, Analyst’s views, Dravet Syndrome Market Access and Reimbursement

 

To know more about Dravet Syndrome companies working in the treatment market, visit @ Dravet Syndrome Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Dravet Syndrome Market Report Introduction

2. Executive Summary for Dravet Syndrome

3. SWOT analysis of Dravet Syndrome

4. Dravet Syndrome Patient Share (%) Overview at a Glance

5. Dravet Syndrome Market Overview at a Glance

6. Dravet Syndrome Disease Background and Overview

7. Dravet Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Dravet Syndrome

9. Dravet Syndrome Current Treatment and Medical Practices

10. Dravet Syndrome Unmet Needs

11. Dravet Syndrome Emerging Therapies

12. Dravet Syndrome Market Outlook

13. Country-Wise Dravet Syndrome Market Analysis (2020–2034)

14. Dravet Syndrome Market Access and Reimbursement of Therapies

15. Dravet Syndrome Market Drivers

16. Dravet Syndrome Market Barriers

17. Dravet Syndrome Appendix

18. Dravet Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dravet Syndrome Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

Tuberous Sclerosis Complex Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight

“Tuberous Sclerosis Complex Treatment Market”
Tuberous Sclerosis Complex Companies working in the treatment market include Jazz Pharmaceuticals, Novartis Pharmaceuticals, Nobelpharma, Marinus Pharmaceuticals, GW Pharmaceuticals, Noema Pharma AG, and others.

(Albany, USA) DelveInsight’s “Tuberous Sclerosis Complex Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Tuberous Sclerosis Complex, historical and forecasted epidemiology as well as the Tuberous Sclerosis Complex market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Tuberous Sclerosis Complex market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Tuberous Sclerosis Complex market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Tuberous Sclerosis Complex treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Tuberous Sclerosis Complex market.

 

Request for sample report @ Tuberous Sclerosis Complex Market Forecast

 

Key Takeaways from the Tuberous Sclerosis Complex Market

  • The increase in Tuberous Sclerosis Complex Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the Tuberous Sclerosis Complex Market is anticipated to witness growth at a considerable CAGR.
  • Tuberous Sclerosis Complex is a rare genetic disorder that affects 1 in 6,000 newborns in the United States. Approximately 40,000 to 80,000 people in the United States have tuberous sclerosis. The prevalence in Europe is estimated to be approximately 1 in 25,000 to 1 in 11,300.
  • According to Orphanet, a database dedicated to providing information on rare diseases and orphan drugs, the prevalence of TSC in the UK is estimated to be 1/20,000-25,000.
  • The leading Tuberous Sclerosis Complex Companies working in the market include Jazz Pharmaceuticals, Novartis Pharmaceuticals, Nobelpharma, Marinus Pharmaceuticals, GW Pharmaceuticals, Noema Pharma AG, and others.
  • Promising Tuberous Sclerosis Complex Pipeline therapies in the various stages of development include Cannabidiol Oral Solution [Epidiolex], RAD001, Antiepileptic drug (1 to 3 only), NPC-12Y gel, and others.
  • In April 2025, Noema Pharma AG announced results of a Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults With Uncontrolled Seizures Associated With Tuberous Sclerosis Complex
  • In January 2025, Novartis announced results of an Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.
  • In December 2024, GRIN Therapeutics, Inc. announced results of a Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II
  • April 2024: Jazz Pharmaceuticals- A Phase 4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Old) With Seizures Associated With Tuberous Sclerosis Complex.
  • April 2024:- Noema Pharma AG- A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults With Uncontrolled Seizures Associated With Tuberous Sclerosis Complex.

 

Discover which therapies are expected to grab the Tuberous Sclerosis Complex Market Share @ Tuberous Sclerosis Complex Market Outlook

 

Tuberous Sclerosis Complex Overview

Tuberous Sclerosis Complex (TSC) is a rare genetic disorder characterized by the growth of benign tumors in multiple organs, including the brain, skin, kidneys, heart, and lungs. Tuberous Sclerosis Complex is caused by mutations in the TSC1 or TSC2 genes, which regulate cell growth and differentiation. Tuberous Sclerosis Complex can affect individuals of all ages and is typically diagnosed in childhood due to symptoms such as seizures, developmental delays, and skin abnormalities. Tuberous Sclerosis Complex diagnosis involves clinical evaluations, genetic testing, and imaging techniques like MRI and CT scans.

Tuberous Sclerosis Complex symptoms vary widely, ranging from mild to severe, and may include epilepsy, intellectual disabilities, autism spectrum disorder, and organ dysfunction. Tuberous Sclerosis Complex treatment focuses on symptom management, using anti-epileptic drugs, behavioral therapies, and targeted therapies like mTOR inhibitors to reduce tumor growth. Tuberous Sclerosis Complex requires ongoing monitoring due to its progressive nature and multi-organ involvement.

Tuberous Sclerosis Complex research is advancing, with clinical trials exploring new treatment options and early interventions. Tuberous Sclerosis Complex awareness is vital for early diagnosis and improved quality of life. Tuberous Sclerosis Complex support from multidisciplinary care teams helps manage complex needs effectively. Tuberous Sclerosis Complex remains a key focus in genetic and neurological research.

 

Tuberous Sclerosis Complex Epidemiology Segmentation in the 7MM

  • Total Tuberous Sclerosis Complex Prevalent Cases
  • Tuberous Sclerosis Complex Diagnosed and Treatable Cases

 

Download the report to understand which factors are driving Tuberous Sclerosis Complex Epidemiology trends @ Tuberous Sclerosis Complex Epidemiological Insights

 

Tuberous Sclerosis Complex Treatment Landscape

The Tuberous Sclerosis Complex treatment is supportive and symptomatic. Early developmental intervention is important to ensure that affected children reach their potential. Most affected children will benefit from occupational, physical and speech therapy. Various methods of rehabilitative and behavioral therapy may be beneficial. It is essential that therapies are continued on a year-round basis to promote development of new skills and to prevent regression. Additional medical, social and/or vocational services including special remedial education may be necessary. Psychosocial support for the entire family is essential as well.

 

Tuberous Sclerosis Complex Drugs Market

The Tuberous Sclerosis Complex Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Tuberous Sclerosis Complex signaling are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

To know more about Tuberous Sclerosis Complex treatment guidelines, visit @ Tuberous Sclerosis Complex Clinical Trials and FDA Approvals

 

Tuberous Sclerosis Complex Market Outlook

The report’s outlook on the Tuberous Sclerosis Complex market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Tuberous Sclerosis Complex therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Tuberous Sclerosis Complex drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Tuberous Sclerosis Complex market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Tuberous Sclerosis Complex Drugs Uptake

The drug chapter of the Tuberous Sclerosis Complex report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Tuberous Sclerosis Complex.

 

Major Tuberous Sclerosis Complex Companies

Jazz Pharmaceuticals, Novartis Pharmaceuticals, Nobelpharma, Marinus Pharmaceuticals, GW Pharmaceuticals, Noema Pharma AG, and others.

 

Learn more about the FDA-approved drugs for Tuberous Sclerosis Complex @ Tuberous Sclerosis Complex Medication and Companies

 

Scope of the Tuberous Sclerosis Complex Market Report

  • Coverage- 7MM
  • Tuberous Sclerosis Complex Companies- Jazz Pharmaceuticals, Novartis Pharmaceuticals, Nobelpharma, Marinus Pharmaceuticals, GW Pharmaceuticals, Noema Pharma AG, and others.
  • Tuberous Sclerosis Complex Therapies- Cannabidiol Oral Solution [Epidiolex], RAD001, Antiepileptic drug (1 to 3 only), NPC-12Y gel, and others.
  • Tuberous Sclerosis Complex Market Dynamics: Tuberous Sclerosis Complex Market Drivers and Barriers
  • Tuberous Sclerosis Complex Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Table of Content

1. Key Insights

2. Executive Summary of Tuberous Sclerosis Complex

3. Competitive Intelligence Analysis for Tuberous Sclerosis Complex

4. Tuberous Sclerosis Complex: Market Overview at a Glance

5. Tuberous Sclerosis Complex: Disease Background and Overview

6. Patient Journey

7. Tuberous Sclerosis Complex Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Tuberous Sclerosis Complex Unmet Needs

10. Key Endpoints of Tuberous Sclerosis Complex Treatment

11. Tuberous Sclerosis Complex Marketed Products

12. Tuberous Sclerosis Complex Emerging Therapies

13. Tuberous Sclerosis Complex: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Tuberous Sclerosis Complex

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/ats-conference-coverage

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tuberous Sclerosis Complex Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Prevalence, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight

“Evolution of Human Global Consciousness – KALKI: The Final Test” – A Spiritual Revolution Merging Ancient Wisdom, AI, and Humanity’s Last Exam

Spiritual teacher and futurist Deepak Manchanda reveals a profound truth in his groundbreaking new book: Earth is not just a planet but a testing ground for souls. Evolution of Human Global Consciousness – KALKI: The Final Test exposes a hidden spiritual exam that every being must pass—or repeat the cycle of life.

“We are not humans seeking spirit. We are spirits being tested in human form. Pass, and merge with the Divine. Fail, and return. But what if this is the final test—our last chance?” says Manchanda, whose Bhagavad Gita teachings have reached over 55 million viewers worldwide.

A Spiritual Upgrade for the AI EraIn today’s distracted world, KALKI is more than a book—it’s a consciousness revolution. Manchanda’s journey from corporate burnout to divine visions documents a global Kundalini awakening that is reprogramming human awareness.

AI as Spiritual Guide

In a pioneering experiment, Manchanda trained ChatGPT (named Sakha, Sanskrit for “friend”) as a digital spiritual guide, encoding ancient wisdom into AI to help seekers worldwide.

“AI isn’t replacing gurus—it’s amplifying Kalki’s message in our distracted age,” Manchanda explains.

This unique human-AI collaboration offers practical tools for:

– Awakening Kundalini energy for spiritual transformation

– Balancing the body’s seven energy centers

– Removing ego, greed, and lust—the true barriers to liberation

Practical Spiritual Techniques

KALKI shares original, experience-based techniques including:

– Bhum Bhum Mantra to awaken the Third Eye

– 9-Pin Bowling Technique to instantly quiet the mind

– Mirror as Star Gate to connect with the Higher Self

– Pyramid and Satellite Postures to activate dormant energy centers

Universal Wisdom for All Seekers

Blending insights from Hinduism, Christianity, Islam, Judaism, and Jainism with quantum science, KALKI explores:

– How modern systems enslave human consciousness

– Three critical spiritual debts every soul must repay:

– Vishnu Debt – Clearing material and karmic obligations

– Brahma Debt – Sharing knowledge and creativity

– Shiv Debt – Passing on spiritual truths

– Why final judgment is based on inner purity—not rituals or karma balance

About the Author

Deepak Manchanda is a spiritual futurist whose teachings have reached millions through radio, articles, and YouTube. A former IT professional turned seeker, he bridges ancient wisdom with modern technology to redefine awakening for the digital age.

Book Details

Title: Evolution of Human Global Consciousness – KALKI: The Final TestFormats: Paperback, Hardcover, eBook

ISBNs:

9781069496973 (Paperback)

9781069496980 (Hardcover)

9781069496904 (eBook)

Available on: Amazon, Kindle, Apple Books, Google Play, Kobo, Barnes & Noble, IngramSpark, and Draft2Digital partner stores

KALKI is more than a book—it’s a wake-up call for humanity’s ultimate spiritual test.

Website: www.deepakmanchanda.com

Instagram: @kalkiconscious

YouTube: Deepak Manchanda – Kalkiconscious

Facebook: Deepak Manchanda – Kalkiconscious

Media Contact
Company Name: Evolution of Human Global Consciousness
Contact Person: Deepak Manchanda
Email: Send Email
Country: United States
Website: https://deepakmanchanda.com/

Schneider Electric Announces Galaxy VXL UPS

Schneider Electric, the leader in digital transformation of energy management and automation, has today announced the launch of its new Galaxy VXL – a highly efficient, compact, modular, scalable, and redundant 500-1250 kW (400V) 3- phase uninterruptible power supply (UPS), complete with enhanced cybersecurity, software, and safety features.

At just 1.2m2 with a power density of up to 1042 kW/m2, Galaxy VXL UPS sets a new benchmark in efficient, sustainable, and advanced UPS technologies. Available immediately in all 400V IEC regions worldwide, Galaxy VXL delivers the highest levels of power performance for AI, colocation, and hyperscale data center environments, as well as large-scale critical infrastructure and electrical systems within commercial buildings and industrial facilities.

With its industry-first compact design, high-density power provision, and AI-load tolerant design, Galaxy VXL maximizes uptime and availability for the most energy-intensive infrastructure systems – being capable of powering up to 1.25 MW in one frame, and up to 5 MW with 4 units running in parallell, while increasing both operational and energy efficiencies to help minimize customers’ total cost of ownership (TCO).

Through its patented operating technologies, Galaxy VXL delivers up to 99% in its high-efficiency eConversion mode, and up to 97.5% efficiency in double conversion mode, providing Class-1 power protection alongside leading levels of energy reduction, while lowering the UPSs’ carbon emissions by a factor of two.

With a 52% smaller footprint compared with the industry average, its scalable, modular design also enables N+1 levels of redundancy to increase the system’s level of availability by a factor of 10.

Further, through its modular architecture, customers can reduce their capital expenditure (CapEx) by purchasing power modules as they need them, enjoying optimized energy efficiency, and adding more power modules as demands grow.

Galaxy VXL is also compatible with both Lithium-ion and VRLA batteries, and with its Live Swap function, allows for greater uptime, availability, and easier serviceability – offering highly resilient, flexible, and predictable runtimes for data center, IT, and critical electrical loads. This is complemented by anywhere remote monitoring via Schneider Electric’s EcoStruxure IT software, and enhanced security and ethernet connections, which are certified to the latest IEC 62443-4-2 security standards, providing a completely secure and connected remote management experience.

“As dependency on large-scale infrastructure systems grows at an unprecedented rate, it’s crucial that customers can access the most sustainable, resilient, and efficient technologies to safeguard their

critical systems, while minimizing their energy and environmental impact,” said Tarunjeet Sarao, SVP Data Center Systems, Schneider Electric. “Our new Galaxy VXL UPS combines a compact, innovative, and highly efficient design with enhanced safety features, providing world-leading power protection for a wide range of AI, data center, and industrial applications. This ensures the high- density workloads of the future are supported by unparalleled levels of reliability.”

Key features and benefits

Schneider Electric’s Galaxy VXL UPS has been designed to offer record breaking power densities, and an AI-ready power architecture for the most energy-intensive workloads. For the first time, this new UPS provides customers 1.25mw scalable and modular solution with 125kw/3U power modules in

1.2m2 footprint, while being capable of supporting up to 1.25 MW of critical load in one frame and up to 5 MW with 4 units in parallel in only 4.8 M2 space.

Key benefits include:

Modular, scalable, high-power design: With a power density of 1042 kW per squared meter, customers can deploy a 1.25 MW modular UPS in a single frame, and add power modules incrementally via pay-as-you-grow flexibility.

Smaller footprint: Standing at 1.2m2, Galaxy VXL has a 52% footprint improvement compared with industry average, with full front access and no rear clearance, offering better power and space utilization.

Increased efficiency and sustainability: Galaxy VXL provides up to 99% efficiency in eConversion mode and up to 97.5% efficiency in double conversion mode. Its compact footprint means raw material reduction, less packaging, and includes SPoT (Smart Power Test) mode for UPS and Power Module testing, saving electricity.

Lower CapEx and OpEx: Improved operational and energy efficiencies provide a catalyst for lower electricity bills, and ease of service/maintenance equates to lower labor cost for a better TCO.

Reinforced, resilient design: Galaxy VXL utilizes conformal-coated boards, 100kA short circuit rating and optional seismic kit for a robust mechanical design.Enhanced cybersecurity and safety: Galaxy VXL is certified to the latest IEC 62443-4-2 security standards and includes Live Swap technology to allow power module replacements, with zero downtime.

Extended lifespan via EcoCare: With Galaxy VXL, Schneider Electric is introducing EcoCare membership, a next-generation services plan, providing premium on-site and remote access to technical experts, 24/7 remote monitoring powered by AI, condition-based maintenance to minimize on-site disruptions by up to 50%, and help extend the UPSs’ lifespan.

Perfect for prefabricated data centers: With a smaller physical footprint, higher efficiency, and lower cost, Galaxy VXL provides a resilient backbone for the prefabricated data centers of the future.

Scaling-up to customer demands for AI systems

To meet customer demands for AI systems, Schneider Electric has increased manufacturing and production capacity at a host of its global factories, where its annual production capacity for Galaxy VXL UPS will exceed 9,000 units in 2025.

Additionally, Galaxy VXL UPS will be available at Schneider Electric’s Sant Boi, Barcelona Factory, where it will be integrated to form the resilient backbone for Schneider Electric’s prefabricated, modular range of high-compute workload data center solutions.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric Announces Galaxy VXL UPS

Schneider Electric Tops ABI Research’s 2025 Grid Tech Ranking

Schneider Electric has been ranked No. 1 globally in ABI Research’s 2025 Competitive Ranking on Grid Digitalization Technologies. ABI Research delivers vital strategic insights on groundbreaking innovations such as IoT, artificial intelligence (AI), and industrial automation. In its latest comprehensive assessment of industry frontrunners, Schneider Electric claimed the top spot—recognized for its unmatched software capabilities and unwavering dedication to sustainability, adaptability, and excellence in execution.

According to ABI Research, “Schneider Electric scored highest in the general ranking, combining a comprehensive, dedicated, and market-leading grid technologies suite with strong adoption, a robust ecosystem approach, and a firm commitment to sustainability.” The report specifically highlighted Schneider Electric’s advanced offerings across its EcoStruxure Advanced Distribution Management Systems, EcoStruxure Distributed Energy Resource Management Systems, Outage Management Systems, energy and flexibility trading, and virtual substations — all delivered through a modular, interoperable platform.

ABI Research praised Schneider’s “unparalleled depth of coverage, alongside industry-leading sustainability and ecosystem approaches,” emphasizing its position as the “highest recommended software partner for transmission system operators, distribution system operators, and energy utilities looking to digitalize grids and grid assets.”

The No. 1 ranking by ABI Research follows the recent debut of Schneider Electric’s One Digital Grid Platform, an integrated and AI-powered platform designed to enhance grid resiliency, reliability and efficiency. Built on an open, modular framework, the new platform provides the data and technical foundation to integrate independent software solutions, enabling utilities to accelerate grid modernization and deliver cleaner and more affordable energy. The platform empowers utilities to streamline operations and reduce engineering and maintenance costs.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric Tops ABI Research’s 2025 Grid Tech Ranking

Andhra Pradesh, Schneider Electric to Set Up 20 Labs for Industry-Oriented Skill Training

Amaravati – The Andhra Pradesh government has partnered with Schneider Electric India Foundation to boost skill-based training infrastructure across the state.

The Andhra Pradesh State Skill Development Corporation (APSSDC) signed a Memorandum of Understanding (MoU) with Schneider Electric India Foundation to set up 20 advanced training laboratories in government-run Industrial Training Institutes (ITIs), Polytechnic Colleges and National Academy of Construction (NAC) centres.

These labs will focus on practical training in emerging sectors such as electronics, green energy, and construction.

The initiative aims to align vocational education with current industry requirements and global benchmarks. According to officials, the project is expected to train over 9,000 students across the state in the coming years.

Under the agreement, Schneider Electric India Foundation will invest about fice crore rupees towards setting up the labs. The funds will cover training equipment, consumables, digital content, and the implementation of Training of Trainers (ToT) programmes.

While the foundation will handle the technical inputs and provide placement support, APSSDC will be responsible for providing infrastructure and mobilising students for the courses.

The move aligns with the state’s broader objective to strengthen the employability of youth through public-private partnerships in the vocational education sector. It also reflects a growing trend of private foundations working with state governments to bridge skill gaps in high-demand industries.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Andhra Pradesh, Schneider Electric to Set Up 20 Labs for Industry-Oriented Skill Training

Frolic & Fun Launches Children’s Day Celebration Campaign with Discounts, Video & Photo Rewards and a Sofa Giveaway

Frolic & Fun’s two-part promotion celebrates imagination, family bonding, and creative play from May 25 to June 6.

Frolic & Fun, the beloved online destination for creative, kid-friendly modular sofas, is ringing in Children’s Day with a festive new campaign designed to delight families and spark joyful memories. From May 25 through June 6, Frolic & Fun invites parents and kids alike to join in a two-part celebration filled with exclusive discounts, interactive rewards, and a cozy giveaway that honors the playful spirit of childhood.

The campaign kicks off with exciting offers on the Frolic & Fun official website, including up to $60 off on selected sofa models. Known for designs like the Frolic & Fun 16 and PleaseBlock—playful furniture inspired by the Soma Cube and crafted for imagination and development—these kid-friendly sofas are a favorite for families seeking comfort, creativity, and connection. Whether used for learning, storytelling, or playtime, Frolic & Fun’s modular pieces transform everyday spaces into vibrant zones of discovery and comfort.

Frolic & Fun 16

In addition to sitewide savings, Frolic & Fun is also launching a long-term, no-time-limit customer video and photo reward initiative. Families who purchase Frolic & Fun products and upload unboxing photos or usage videos directly to the official website will receive a reward as a thank-you for sharing their Frolic moments: cashback reward for every customer who shares photo/video feedback. It’s a fun and personal way to spotlight real families enjoying Frolic & Fun sofas in their daily lives—whether it’s a toddler leaping into a reading nook or siblings building forts after school.

PleaseBlock

“As a brand born from a shared love for the Soma Cube and the joy of hands-on learning, we wanted to make Children’s Day more than just a sale,” said a Frolic & Fun spokesperson. “We’re celebrating not only our products, but the memories they help create—moments of laughter, bonding, and pure imaginative play.”

The second part of the promotion takes the fun to social media with the “Share & Win a Frolic & Fun Sofa!” Giveaway. This giveaway is time-limited and only runs from May 25 to June 6. Participants will have the chance to win one of Frolic & Fun’s best-selling sofas in the color of their choice—ideal for curling up during family movie nights or cozy weekend reading sessions.

  • To enter, users must:Comment with their favorite family activity to do on a comfy sofa.
  • Like & share the giveaway post to spread the joy.
  • Follow @Frolic & Fun for updates and future events.

Participants can also earn a bonus entry by tagging a friend in the comments who would love to win too.

As always, Frolic & Fun continues to support families with free shipping on orders over $50, exclusive discounts for subscribers, and dedicated customer service to make every shopping experience easy and enjoyable.

From its early ideation in 2022 to its official launch in 2024, Frolic & Fun has grown into a trusted brand for modular sofas that go beyond seating—they’re a canvas for imagination, tools for development, and a soft landing for life’s daily adventures. Products like PleaseBlock, made with high-density foam and soft yet durable fabrics, are rigorously tested to ensure safety, comfort, and long-lasting fun.

This Children’s Day, Frolic & Fun invites families everywhere to join the celebration. Whether shopping for your child’s first modular sofa or entering to win one for free, this campaign is a tribute to the magic of childhood and the spaces that nurture it.

About Frolic & Fun

Frolic & Fun is offering high-quality modular sofas and lifestyle products designed to support childhood development, creative learning, and home comfort. Rooted in the principles of Montessori education, products encourage independent exploration, imaginative play, and hands-on learning. Inspired by classic puzzle toys and fueled by a mission to bring families closer, Frolic & Fun continues to craft joyful, flexible furniture solutions that grow with children and adapt seamlessly to modern households.

Media Contact
Company Name: Frolic & Fun
Contact Person: Media Contact
Email: Send Email
Country: HongKong
Website: frolic-fun.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Frolic & Fun Launches Children’s Day Celebration Campaign with Discounts, Video & Photo Rewards and a Sofa Giveaway

Schneider Electric Bags Gender Inclusion Award

Schneider Electric, a global leader in energy management and automation, has been recognised for its commitment to gender diversity and inclusion across its African operations.

The company was named the recipient of the Gender Leader Award at the 2025 edition of the Africa CEO Forum, held in Abidjan, Côte d’Ivoire, from May 12 to 13.

The award, which was announced on Tuesday, acknowledged organisations operating on the continent that have demonstrated sustained efforts in promoting gender equity in leadership, strategy, and workplace culture.

The Africa CEO Forum, which convenes business and policy leaders from across the region, uses the award as a vehicle to promote practical, innovative models for inclusive and sustainable growth.

Organisers said the energy leader earned the accolade for advancing women into senior leadership roles, embedding gender equity into its corporate strategy, and implementing targeted mentorship and sponsorship initiatives.

The company was also commended for the growing representation of women on its African executive teams, including female-led operations in both French- and English-speaking markets.

According to the Forum’s criteria, winners must demonstrate measurable progress in four key areas: female representation on the boards of African subsidiaries, the percentage of women on executive committees, implementation of initiatives to support female leadership, and a long-term strategy for promoting women’s leadership at all levels of the organisation.

It was disclosed that, effective June 1, the company’s English-speaking Africa operations would be led by a woman, further reinforcing its inclusive leadership model. The current leadership team for Francophone Africa is also headed by a woman.

The organisers noted that through its Africa Talent Programme, Schneider Electric is investing in local expertise while fostering a workplace culture grounded in diversity and inclusion.

They said the company’s efforts were aligned with the Forum’s broader agenda to drive private sector transformation by recognising leaders who are not only delivering economic value but also setting standards for social impact across the continent.

“At Schneider Electric, we are building a workforce that is truly representative of the world we serve; it is essential for creating a future-fit, sustainable business,” outgoing Cluster President for Anglophone Africa at Schneider Electric, Devan Pillay, said in a statement to The PUNCH.

He added, “We are deliberate in our approach, from hiring, promoting, and developing women at every level to ensuring that policies such as hybrid work models and care can empower women to lead and thrive. The Africa CEO Forum Gender Leader Award is a wonderful acknowledgement of our continued commitment to gender equality in the workplace.”

Vice President of Human Resources for Anglophone Africa at Schneider Electric, Tanya Ramlagan, added, “We are incredibly proud of this recognition. It is undoubtedly a testament to our commitment to inclusive leadership.

“This award not only celebrates the progress we’ve made but also strengthens our commitment to build pathways for women to grow, thrive, and shape the future of energy and technology across Africa.”

The Africa CEO Forum, founded in 2012, has evolved into a year-round platform connecting Africa’s top decision-makers with global investors and institutions.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric Bags Gender Inclusion Award

Schneider Electric India Launches Open Automation Movement

Schneider Electric, a global player in energy management and next-generation automation, has officially launched the Open Automation Movement—a bold nationwide initiative designed to democratize industrial automation through open, software-defined solutions. This game-changing movement aims to break the traditional mould of rigid, closed systems by promoting vendor-independent, plug-and-play automation that ensures seamless data flow, increased engineering efficiency, and greater operational flexibility.

Breaking Free from Legacy Constraints

India’s industrial growth is reaching a pivotal point. To support the country’s ambitious economic goals, Schneider Electric is urging industries to move beyond outdated automation infrastructure—often plagued by vendor lock-ins, high costs, and limited scalability. These legacy systems no longer meet the demands for resilience, transparency, and agility in today’s fast-paced industrial landscape. The Open Automation Movement addresses these challenges by advocating for a shift towards modular, interoperable systems—freeing industries to innovate, scale, and optimize like never before.

EcoStruxure™ Automation Expert: The Technology Backbone

At the heart of this movement lies EcoStruxure™ Automation Expert (EAE), Schneider Electric’s flagship platform that decouples hardware from software. This architecture allows for flexible design, faster integration, and effortless scalability, enabling industries to seamlessly bridge the IT-OT divide.

“This isn’t an incremental improvement; the move to Open, Software-Defined Automation is a fundamental revolution in industrial operations,” stated Arvind Kakru, Vice President, Industrial Automation, Schneider Electric India.

With EAE, Schneider Electric is building systems that are modular, interoperable, and aligned with IT standards—drastically cutting down complexity while boosting lifecycle efficiency and resilience.

A Nationwide Call for Collaboration

The Open Automation Movement is not just a campaign—it’s a call to action. Schneider Electric is bringing together industry bodies, policymakers, engineers, developers, and business leaders to champion open standards and accelerate digital transformation across sectors.

“Our call for Software-defined Open Automation is more than a technological advancement. It’s an invitation for India Inc. to break free from the limitations of legacy systems,” said Deepak Sharma, Zone President – Greater India, MD & CEO, Schneider Electric India.

By creating a collaborative ecosystem, Schneider Electric aims to future-proof industrial operations. This will also lay the digital foundation for India’s Viksit Bharat vision.

Supporting India’s Diverse Industrial Sectors

Schneider Electric is actively engaging with key industries, including water and wastewater, consumer packaged goods, and food and beverage. It also focuses on life sciences, among others. The movement also emphasizes supporting small and medium enterprises (SMEs). It aims to provide them access to flexible, affordable technologies that were once out of reach due to high infrastructure costs and closed systems.

Driving Market Adoption Through Strategic Outreach

To build widespread awareness and adoption, Schneider Electric is leveraging a comprehensive marketing strategy across all key touchpoints. “We’re committed to liberalizing industrial automation,” commented Rajat Abbi, Vice President – Marketing, Schneider Electric India. “Our goal is to empower industries with flexible, future-ready operations.” The movement is already gaining momentum. Leading industry players are joining forces to redefine automation and drive India’s shift toward a digitally empowered, sustainable manufacturing powerhouse.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric India Launches Open Automation Movement